Key result
Intracoronary transplantation of autologous freshly isolated bone marrow cells significantly increased left ventricular ejection fraction and reduced infarct size at 6 months compared to control.
Why the study?
Does intracoronary autologous freshly isolated bone marrow cell transplantation improve left ventricular ejection fraction and reduce infarct size in patients with acute myocardial infarction?
Does intracoronary autologous freshly isolated bone marrow cell transplantation improve left ventricular ejection fraction and reduce infarct size in patients with acute myocardial infarction?
Absolute Event Rate: 55% vs 46%
p-value: p=<0.001
Intracoronary transplantation of freshly isolated autologous bone marrow cells using a point-of-care system is safe and significantly improves left ventricular ejection fraction and reduces infarct size at 6 months in patients with acute myocardial infarction.
BACKGROUND: We analyzed in the present study the influence of intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs-Tx) on cardiac function in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: The 32 patients with AMI were enrolled in this prospective nonrandomized study to either freshly isolated BMC-Tx or to a control group without cell therapy. Global left ventricular ejection fraction (LVEF) and the size of infarct area were determined by left ventriculography. We observed in patients with autologous freshly isolated BMCs-Tx at 6 months follow up a significant reduction of infarct size as compared to control group. Moreover, we found a significant increase of LVEF as well as infarct wall movement velocity at 6 months follow up in cell therapy group as compared to control group. In the control group there was no significant difference of LVEF, infarct size and infarct wall movement velocity between baseline and 6 months after AMI. CONCLUSIONS: These results demonstrate for the first time that intracoronary transplantation of autologous freshly isolated BMCs by use of a point of care system is safe, and may lead to improvement of cardiac function in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Turan et al. (2011) studied Acute Myocardial Infarction (n=32). Intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs-Tx) vs. Control group without cell therapy was evaluated on Change in left ventricular ejection fraction (LVEF) at 6 months (p=<0.001). Intracoronary transplantation of autologous freshly isolated bone marrow cells significantly increased left ventricular ejection fraction and reduced infarct size at 6 months compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: